Literature DB >> 18053719

Dropped head syndrome as prominent clinical feature in MuSK-positive Myasthenia Gravis with thymus hyperplasia.

Konstantinos Spengos1, Sofia Vassilopoulou, Georgios Papadimas, Georgios Tsivgoulis, Nikos Karandreas, Thomas Zambelis, Panagiota Manta.   

Abstract

MuSK-positive Myasthenia Gravis is in most cases clinically characterized by a progressive course with severe oculobulbar involvement or prominent neck, shoulder and respiratory muscle weakness. It is also distinguished from other forms of myastehnia through its lack of germinal centers or lymphocytic infiltrates in the thymic tissue. We present the case of a MuSK-positive female myasthenic patient with over four years slowly progressive weakness of the neck extensor muscles in the presence of thymus hyperplasia and discuss its uncommon and markedly focal clinical and electrophysiological features, as well as the excellent course under medication with pyridostigmine and prednisone, especially after thymectomy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18053719     DOI: 10.1016/j.nmd.2007.09.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  4 in total

Review 1.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

2.  Dropped head with positive intravenous edrophonium, progressing to myasthenia gravis.

Authors:  Nobuhiro Sawa; Hiroshi Kataoka; Nobuyuki Eura; Satoshi Ueno
Journal:  BMJ Case Rep       Date:  2013-01-31

3.  Dropped head syndrome due to neuromuscular disorders: Clinical manifestation and evaluation.

Authors:  Ahmet Z Burakgazi; Perry K Richardson; Mohammad Abu-Rub
Journal:  Neurol Int       Date:  2019-06-19

4.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.